Rangering i aksjer
#40642
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Aksjekurs
$0.00323826
Sist synkronisert: 2026-08-12
Handel Purple Biotech Ltd. (PPBT)
P/S-forhold for Purple Biotech Ltd. (PPBT)
P/S-forhold per 2026 TTM: 0
Ifølge Purple Biotech Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Purple Biotech Ltd. fra 2026 til 2026
P/S-forhold ved hvert års slutt
| År |
P/S-forhold |
Endre |
|
Ikke nok data for de angitte datoene. |
P/S-forhold for lignende selskaper eller konkurrenter
| Selskap |
P/S-forhold |
Forskjell i P/S-forhold |
Land |
|
|
9.88 |
-
|
US
|
|
|
10.30 |
-
|
NL
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
|
|
4.98 |
-
|
BE
|
